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Abstract 
Lectins (Ls) play an important role in many diseases such as different types of cancer, parasitic infections and other 
diseases. Interestingly, the Protein Data Bank (PDB) contains +3000 protein 3D structures with unknown function. 
Thus, we can in principle, discover new Ls mining non-annotated structures from PDB or other sources. However, 
there are no general models to predict new biologically relevant Ls based on 3D chemical structures. We used the 
MARCH-INSIDE software to calculate the Markov-Shannon 3D electrostatic entropy parameters for the complex 
networks of protein structure of 2200 different protein 3D structures, including 1200 Ls. We have performed a Linear 
Discriminant Analysis (LDA) using these parameters as inputs in order to seek a new Quantitative Structure-Activity 
Relationship (QSAR) model, which is able to discriminate 3D structure of Ls from other proteins. We implemented 
this predictor in the web server named LECTINPred, freely available at http://bio-aims.udc.es/LECTINPred.php. This 
web server showed the following goodness-of-fit statistics: Sensitivity=96.7 % (for Ls), Specificity=87.6 % (non-
active proteins), and Accuracy=92.5 % (for all proteins), considering altogether both the training and external 
prediction series. In mode 2, users can carry out an automatic retrieval of protein structures from PDB. We illustrated 
the use of this server, in operation mode 1, performing a data mining of PDB. We predicted Ls scores for +2000 
proteins with unknown function and selected the top-scored ones as possible lectins. In operation mode 2, 
LECTINPred can also upload 3D structural models generated with structure-prediction tools like LOMETS or 
PHYRE2. The new Ls are expected to be of relevance as cancer biomarkers or useful in parasite vaccine design. 
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1. Introduction 
Lectins (Ls) are proteins involved in very important biological processes. Innate immunity is the 
earliest response to invading microbes/parasites and it acts to contain infection in the first minutes to 
hours of challenge. Unlike adaptive immunity that relies upon clonal expansion of cells that emerge days 
after antigenic challenge, the innate immune response is immediate. In fact, C-type Ls receptors (CLRs) 
have long been known as pattern-recognition receptors involved in the recognition of pathogens by the 
innate immune system.1 However, evidence is accumulating that many CLRs are also able to recognize 
endogenous self-ligands and that this recognition event often plays an important role in immune 
homeostasis.2 Geijtenbeek and Gringhuis3 reviewed the expression of CLRs by dendritic cells as a 
crucial step for tailoring immune responses to pathogens. Recently, Osanya et al.
[4]
 have shown that 
Leishmania sp. lipophosphoglycan (LPG), a pathogen glycolipid, modulated essential interactions with 
host phagocytic cells, promoting immune-modulation. LPG altered the production of pro-inflammatory 
cytokines via a toll-like receptor (TLR2)-mediated mechanism in vitro and in vivo, in mice infected with 
Leishmania major. The type of inflammation and rate of bead entry into macrophages and dendritic cells 
were different compared with control, indicating selective Ls receptor/oligosaccharide interactions, 
mediating cell entry and cytokine production. In the author’s own words: “these novel findings may 
prompt the development of targeted oligosaccharide adjuvants against chronic infections”. On the other 
hand, the Ls called Galectins have been recognized as important mediators of immune homeostasis and 
disease regulation, but comparatively little is known about their role in parasite infection. In this sense, 
Young et al.5 have published this year the following work: Galectin secretion and binding to adult 
Fasciola hepatica during chronic liver fluke infection of sheep. This work showed that both galectin-14 
and galectin-11 directly interact with the parasite in the bile ducts after being released in liver tissue 
during chronic liver fluke infection. Galectin-11 may also be involved in epithelial cell turnover and 
cancerogenesis. In addition, fluorescently-labeled Ls have been used to uncover hidden antigens in 
parasites like Fasciola in vaccine design preliminary efforts.6 Soluble mediators, including complement 
components and the Mannose-Binding Lectin (MBL) make an important contribution to innate immune 
protection and work along with epithelial barriers, cellular defenses such as phagocytosis, and pattern-
recognition receptors that trigger pro-inflammatory signaling cascades. Ip and Takahashi et al.7 discussed 
the protection provided by this complex defense system and the particular contribution of soluble 
mediators such as MBL. Several prediction models of the tertiary structure of the lectins have been 
presented by Chou and Geng’s teams.8 
Epidemiological studies have suggested that the genetically determined variations in MBL serum 
concentrations influence the susceptibility to and the course of different types of diseases.9 For instance, 
liver cancer is the predominant cause of cancer mortality in males of Southern China and Taiwan. The 
current therapy is not satisfactory, and more effective treatments are needed. In search for new therapies 
for liver tumor, Lei and Chang10 have found that Concanavalin A (Con-A), a lectin from Jack bean 
seeds, can have a potent anti-hepatoma effect. The prototype of Con-A with an anti-hepatoma activity 
supports the search for other natural Ls as anti-cancer compounds. However, other important uses may be 
expected for new lectin-like proteins. For instance, lectin binding as a biological test in vitro for the 
prediction of functional activity of human spermatozoa11 or a study of pathologic processes using 
phytoLs,12 Winn et al.13 have demonstrated that sialic acid binding Ig-like lectin 6 (Siglec-6) together 
with other proteins could have clinical utility for predicting and/or diagnosing Preeclampsia (PE). PE 
affects 4–8 % of human pregnancies causing significant maternal and neonatal morbidity and mortality. 
Kamoto and Satomura et al.14 assessed the usefulness of lectin-reactive alpha-fetoprotein (AFP-L3 %) in 
hepatocellular carcinomas. Measurement of soluble Lectin-like oxidized LDL receptor (LOX)-1 in vivo 
may provide a novel diagnostic tool for the evaluation and prediction of atherosclerosis and vascular 
disease.15 Noguchi and Thomas et al.16 carried out a further analysis of predictive value of Helix 
pomatia lectin binding to primary breast cancer for axillary and internal mammary lymph node 
metastases. 
All these facts have determined that the discovery of new Ls or Ls-like proteins and/or Ls targeted by 
drug lead compounds has become a goal of major interest. In any case, the number of potential protein 
candidates to be investigated with experimental procedures in order to possibly annotate them as Ls is 
very high. The same happens with a very large number of potential compounds to be studied as inhibitors 
of different Ls. In this sense, the development of new web servers may be very useful to predict different 
types of Ls based on different Machine Learning techniques. For instance, a web server for C-type Ls 
prediction based on Support Vector Machine (SVM) algorithms has been published on the web 
(http://software.iiar.res.in/svm/ctypelectin index.html). Other web server has been developed to predict 
Galectins, also based on SVM (http://software.iiar.res.in/svm/galectin index.html). 
Remarkably, Kumar et al. have developed another SVM-based web server called CancerPred for the 
prediction of Cancer Ls (http://www.imtech.res.in/raghava/cancer_pred/index.html).17 In our opinion, 
Quantitative Structure-Activity Relationship (QSAR)18 and other computational methods may be very 
useful for predicting new Ls proteins and/or compounds having Ls as protein targets. Sirois, Giguere, and 
Roy19 presented the first QSAR model for Galectin-3 glycomimetic inhibitors based on docked structures 
to the carbohydrate recognition domain (CRD). We can use many physicochemical parameters to 
characterize proteins in these studies such as charges or hydrophilicity parameters20 or numerical 
parameters derived from a graph or network representation of the molecular systems (including but not 
limited to protein structure, as in this case).21 However, there is no report of a general QSAR model for 
the prediction of Ls-like proteins. As demonstrated by a series of recent publications,22 to establish a 
really useful statistical predictor for a protein system, we need to consider the following procedures: (i) 
construct or select a valid benchmark dataset to train and test the predictor; (ii) formulate the protein or 
biological samples with an effective mathematical expression or model that can truly reflect their intrinsic 
correlation with the attribute to be predicted; (iii) introduce or develop a powerful algorithm (or engine) 
to operate the prediction; (iv) properly perform cross-validation tests to objectively evaluate the 
anticipated accuracy of the predictor; (v) establish a user-friendly web-server for the predictor that is 
accessible to the public. Below, let us describe how to deal with these steps one by one. 
González-Díaz et al. introduced a new QSAR method that could be useful to solve the Ls prediction 
problem. The method was called MARkovian CHemicals IN SIlico DEsign (MARCH-INSIDE 1.0) for 
the computational design of small-sized drugs. The approach uses a Markov Chain model (MCM) of the 
intra-molecular movement of electrons to calculate structural parameters of drugs. In successive studies, 
we have extended this method to perform fast calculation of 2D and 3D alignment free structural 
parameters based on molecular vibrations in RNA secondary structures, or electrostatic potential, and Van 
der Waals interactions in proteins. Recently, the method has been renamed as MARkov CHains 
Invariants for Networks SImulation & DEsign (MARCH-INSIDE 2.0). This explores more adequately 
the broad uses of the method that describes the structure of drugs,23 RNA,24 and proteins,25,26 as well 
as drug-drug networks,27 and drug-protein interactions.28 The MARCH-INSIDE method may also be 
used to study PPIs, bacteria-bacteria co-aggregation, parasite-host interactions and other systems with an 
MCM associated to a network. In very recent reviews, we have discussed the last applications of this 
method.29–31 We should also make reference to the recent implementation carried out by Munteanu and 
González-Díaz of the Internet portal called Bio-AIMS, freely available for the use of the international 
research community. This portal includes the web-server packages TargetPred (http://bio-
aims.udc.es/TargetPred.php) with new Protein-QSAR servers based on MARCH-INSIDE. One of the 
servers is ATCUNPred,32 useful for predicting ATCUN-mediated DNA-cleavage anticancer proteins. 
The second server is EnzClassPred,33 which implements one of the MARCH-INSIDE-based QSAR 
models for the prediction of enzyme function.34 Two additional servers based on MARCH-INSIDE are: 
Trypano-PPI35 and Plasmod-PPI.36 These are the first servers that predict self protein-protein complexes 
in Trypanosome sp. or Plasmodium sp. Proteomes, opening new opportunities for anti-trypanosome or 
anti-malarial drug target discovery. 
For all these reasons, we decided to develop herein the first 3D-QSAR method useful to discriminate 
between Ls and non-Ls proteins (nLs) using MARCH-INSIDE 2.0. To this end, firstly we have calculated 
different local and global parameters of the 3D residue contact networks of large series of Ls and nLs 
proteins (see Figure 1). The 3D network parameters calculated are of three different classes: average 
electrostatic potentials ξk(R), together with spectral moments of πk(R) and entropy measures θk(R) of the 
electrostatic field of amino acids placed at distance k from each other within different regions R of the 
protein 3D structure. Next, we have carried out a statistical analysis in order to seek a linear equation 
(3D-QSAR model) that links the 3D electrostatic parameters of the protein structural network with S(Ls) 
values. The S(Ls) output is a real-valued variable that scores the propensity of a protein to act as a Ls. In 
addition, we have implemented the model in a public web server for the prediction of these proteins 
called LECTINPred. Last, we have illustrated the use of this web server to carry out online data mining of 
the PDB. We have predicted S(Ls) values for +1000 proteins. This type of study may help us to discover 
new Ls useful as human cancer biomarkers of drug targets. 
  
 
 
 
Figure 1. Flowchart for all the steps necessary to construct the 
classifiers and server. 
2. Computational Methods 
2.1. MARCH-INSIDE Method 
In this work, the information about the molecular structure of the proteins is codified by using the 
MCM method with the 
1Π matrix (the short-term electrostatic interaction matrix). The matrix 1Π is 
constructed as a squared matrix (n×n), where n is the number of amino acids (aa) in the protein.37,38 In 
previous works we have predicted protein function based on 3D-Potentials for different type of 
interactions or molecular fields derived from 
1Π. The main types of the used molecular fields are: E 
(electronegativity), vdW (Van der Waals), and HINT (hydrophobic interaction field) potentials.26,38,39 
In this paper, we have calculated πk(R) and θk(R) values only for E and HINT potentials. We have omitted 
the vdW term due to a simple reason; the HINT potential includes a vdW component. The values have 
been used here as inputs to construct the QSAR model. The detailed explanation has been published 
before. As follows, we give the formula for πk(R), θk(R) and ξk(R) and some general explanations:(1), (2), 
(3) 
 
 
 
 
 
  
It is remarkable that the spectral moments depend on the probability 
k
pij(R) with which the effect of 
the interaction f propagates from amino acid i
th
 to other neighboring amino acids j
th
 and returns to i
th
 after 
k-steps. On the other hand, both the average electrostatic potential and the entropy measures depend on 
the absolute probabilities 
k
pj(R) with which the amino acid j
th
 has an interaction of type f with the rest of 
amino acids. In any case, both probabilities refer to a first (k=1) direct interaction of type f between 
amino acids placed at a distance equal to k-times the cut-off distance (rij=k⋅rcut-off). The method uses a 
Markov Chain Model (MCM) to calculate these probabilities, which also depend on the 3D interactions 
between all pairs of amino acids placed at a distance rij in r3 in the protein structure. However, for the sake 
of simplicity, a truncation or cut-off function αij is applied in such a way that a short-term interaction 
takes place in a first approximation only between neighboring aa (αij=1 if rij<rcut-off). Otherwise, the 
interaction is banished (αij=0). The relationship αij may be visualized in the form of a protein structure 
complex network (see Figure 2). In this network, the nodes are the Cα atoms of the amino acids and the 
edges connect pairs of amino acids with αij=1. Euclidean 3D space r3=(x, y, z) coordinates of the Cα 
atoms of amino acids listed on protein PDB files. For calculation all water molecules and metal ions were 
removed.30 All calculations were carried out with our in-house MARCH-INSIDE 2.0 software.30 Thus, 
the study used the default value of 7 Å for the rcut-off. The MARCH-INSIDE software uses the full matrix 
to calculate the natural powers of the matrix but it can sum the values of all nodes (amino acids) to 
calculate total indices or only for some nodes in order to calculate local protein descriptors. It means that 
MARCH-INSIDE can calculate total values or local values that correspond to the selected amino acids 
placed in specific spatial regions or orbits (R). These regions are often defined in geometric terms and are 
called core, inner, middle or surface region. The protein is virtually divided into the following regions: c 
corresponds to core, i to inner, m to middle, and s to surface regions, respectively. The diameters of the 
regions are 0 to 25 for region c, 25 to 50 for region i, 50 to 75 for region m, and 75 to 100 for region s. 
These values are given in terms of percentage of the longest distance rmax with respect to the centre of 
charge. Additionally, we consider the total region (t) that contains all the amino acids in the protein 
(region diameter 0 to 100 % of rmax). Consequently, we can calculate different parameters (πk(R), ξk(R), 
and θk(R)) for the amino acids contained in a region (c, i, m, s, or t) and placed at a topological distance k 
within this region (k is the name of the order).26,40 In this work, we calculated a total of 90 indices (3 
types of indices×5 types of regions×6 higher order considered) for each protein. 
  
 
 
 
Figure 2. Representations of a lectin with PDBID 3CNA (concanavalin): (A) 3D 
structure model for a full complex and (B) complex network graph. 
2.2. LDA Model 
The Linear Discriminant Analysis (LDA) is frequently used for classification/prediction problems in 
physical anthropology, but it is unusual to find examples in which researchers consider the statistical 
limitations and assumptions required for this technique. In this work, all LDA models have been trained 
with the STATISTICA 6.0 software, for which our laboratory holds rights of use.41 In LDA, we use 
several variable selection techniques to seek the model: i) All Effects (include all parameters), ii) 
Forward-stepwise, iii) Forward-entry, iv) Backward-stepwise, v) Backward-removal, and vi) Best 
subsets. Unless we specify a different value, we always set a prior probability of p(LIBP)=p(nLIBP)=0.5. 
The LDA discriminant equation was obtained using as input the three types of Markov chain invariants 
θk(R). The general form of the equation obtained by LDA is:(4) 
 
 
 
  
S(Ls) is the above-mentioned output of the model. It is a real-valued variable that scores the 
propensity of a protein to act as Ls. The χ2 and p-level value were examined in order to test the statistical 
significance of the model. The Accuracy, Specificity and Sensitivity were used to quantify the goodness-
of-fit and the discriminatory power of the model. Different authors have applied this type of LDA model 
using different classes of input variables to construct QSAR models for drugs,42,43 proteins or nucleic 
acids.43,44 In statistical prediction, the following three cross-validation methods are often used to 
examine a predictor for its effectiveness in practical application: independent dataset test, subsampling or 
K-fold (such as 5-fold and 10-fold) cross-validation test, and jackknife test.45 However, as elucidated in 
Chou46 and demonstrated by Equations 28–32 therein, among the three cross-validation methods, the 
jackknife test is deemed the least arbitrary that can always yield a unique result for a given benchmark 
dataset, and hence has been increasingly used and widely recognized by investigators to examine the 
accuracy of various predictors.47 However, in this study we used the independent dataset to test our 
model in order to reduce the computational time as many investigators did with SVM as prediction 
engine. 
2.3. Dataset 
The protein structures were downloaded from PDB48 using the following schemes for PDB-database 
search: (i) introducing as input parameter the text sugar-binding protein in the search item, called function 
for positive cases. Scheme (ii) was used to get negative cases introducing the PDB IDs for all the proteins 
contained in the list reported in the article published by Dobson and Doig.49 The positive cases are those 
proteins with function annotation as Ls in the PDB. The list of negative cases (nLs) from the search 
scheme (ii) contains enzymes and other proteins present in humans and many other organisms, including 
other parasites (see Supporting Information 1). The nLs proteins have known functions different from Ls. 
The dataset was made up of 2200 proteins (1200 Ls and 1000 nLs) from more than 20 organisms, 
including parasites and human or cattle hosts. Detailed information about the PDB ID, the values of the 
Markov-Shannon electrostatic entropy indices, the corresponding observed classification, and the 
predicted classification for each protein are given in the Supporting Information 2. To avoid homology 
bias and remove the redundant sequences from the benchmark dataset, a cut-off threshold of 25 % is 
normally recommended46 to exclude those proteins from the benchmark datasets that have equal to or 
greater than 25 % sequence identity compared to any other as done in the literature.50 However, in this 
study we have not used such a stringent criterion because the currently available data do not allow us to 
do so. Otherwise, the number of proteins for some subsets would be too low to have statistical 
significance. 
3. Results and Discussion 
3.1. Alignment-Free LDA Model for Ls 
One of our previous works has reported the applicability of the LDA in protein and/or drug QSAR 
studies.51 The best QSAR LDA model in this study is described by Equation 5 and was obtained with the 
Forward stepwise method from STATISTICA:41(5) 
 
 
 
 
 
The statistical parameters of the model are: Canonical Regression Coefficient (Rc), Chi-square (χ
2
) and 
model significance level (p-level).52 N represents only the number of proteins used to train the model. 
We split the dataset at random in a training series (75 %), used for model construction; and a prediction 
one (25 %) used for model validation. The high Rc > 0.8 indicates a strong linear correlation between 
input and output. The value of p-level <0.05 for the Chi-square test indicates a statistically significant 
discrimination between the two groups of proteins. In addition, the model has shown good Accuracy, 
Specificity, and Sensitivity values in both training series and external validation series. The classification 
matrices for the training, validation and both (training + validation together) series are presented in Table 
1 (full dataset). The PDB ID, θk, and S(Ls) values for all proteins used to train or validate (cv) the model 
are given in the Supporting Information 2 (available online). This result confirms a statistically significant 
relationship between MARCH-INSIDE parameters and Ls activity. Taking into consideration that this 
classifier is a simpler linear equation with only nine input parameters we can conclude that this may 
become a very useful model. 
In order to test the possible biases generated by the unbalanced full dataset composition (1000 nLs vs. 
1200 Ls), two additional datasets have been tested: 1 : 1 (1000 nLs vs. 1000 Ls) and 5 : 1 (1000 nLs vs. 
200 Ls). These two datasets have been used to find the same type of classification (LDA), with the same 
five topological indices (see Equation 5) and the same training/validation split (75 % vs. 25 %). The 
dataset 1 : 1 has been used to test the variation of the prediction when the dataset is balanced. The dataset 
5 : 1 represents an extreme test where the number of Ls cases is five times lower than the number of nLs 
cases (closer to the reality). Therefore, these two new datasets have been obtained by randomly removing 
Ls cases. Table 1 demonstrates that the total accuracy prediction (Both, Total Accuracy) of Ls proteins 
with an LDA model based on five TIs is lower with only 0.6 % for the balanced dataset (1 : 1) and it is 
lower with 2.6 % for the close-to-reality composition dataset (5 : 1, nLs : Ls). 
Table 1. Results of the 3D-QSAR study of LIBPs with LDA. 
Data Sub-set Group Parameter % nLs Ls 
      
1000 nLs vs. 1200 Ls (Full dataset) 
     
Training nLs Specificity 88.3 662 88 
  Ls Sensitivity 96.9 28 872 
  Total Accuracy 93.0 
  
Validation nLs Specificity 85.6 214 36 
  Ls Sensitivity 96.0 12 288 
  Total Accuracy 91.3 
  
Both nLs Specificity 87.6 876 124 
  Ls Sensitivity 96.7 40 1160 
  Total Accuracy 92.5 
  
1000 nLs vs. 1000 Ls (1 : 1 dataset) 
     
Training nLs Specificity 88.1 661 89 
  Ls Sensitivity 96.3 28 722 
  Total Accuracy 92.2 
  
Validation nLs Specificity 86.0 215 35 
  Ls Sensitivity 96.0 10 240 
  Total Accuracy 91.0 
  
Both nLs Specificity 87.6 876 124 
  Ls Sensitivity 96.2 38 962 
  Total Accuracy 91.9 
  
1000 nLs vs. 200 Ls (5 : 1 dataset) 
     
Training nLs Specificity 89.9 674 76 
  Ls Sensitivity 90.0 15 135 
  Total Accuracy 89.9 
  
Validation nLs Specificity 89.2 223 27 
  Ls Sensitivity 94.0 3 47 
  Total Accuracy 90.0 
  
Both nLs Specificity 89.7 897 103 
  Ls Sensitivity 91.0 18 182 
  Total Accuracy 89.9 
  
      
  
3.2. LECTINPred web Server 
At the present time, looking for a fast and accurate predictive model is not enough; it should also be 
implemented into public servers available online to the scientific community. The server packages 
developed by Chou and Shen that predict the function of proteins from structural parameters or explore 
protein structures53 are good examples in this sense. These may be used by proteome research scientists 
by interacting with user-friendly interfaces. It means that the user does not need to be an expert on the 
theoretical details behind this kind of models, including the vast literature published by Chou et al. on the 
development of models with pseudo-amino acid composition parameters or the use of Machine Learning 
classification techniques (Artificial Neural Networks, Hidden Markov Models, and Support Vector 
Machines.54 PseAA composition of a protein represents a set of discrete numbers that is derived from its 
amino acid sequence and that is different from the classical amino acid composition. Thus, PseAA is able 
to encode sequence order or pattern information. However, to the best of our knowledge, there is no 
QSAR-based server for the prediction of Ls. In this sense, we have implemented the best LDA model 
found here at the web portal Bio-AIMS as an online server called LECTINPred. The acronym 
LECTINPred comes from the words LECTINs and Predictor. LECTINPred is located at: http://bio-
aims.udc.es/LECTINPred.php. This online tool is based on PHP/HTML and Python routines coupled to 
nested MARCH-INSIDE classic algorithm to calculate input molecular structure parameters.29 
3.2.1. LECTINPred Mode 1 
Figure 3 depicts the user interface for LECTINPred including mode 1 (top of the web page). The user 
only has to paste the PDB ID of the query proteins with unknown functions. With these PDB ID codes, 
LECTINPred automatically connects to the PDB database, uploads the PDB files with the 3D structure of 
the protein, constructs the Markov matrix of electrostatic interactions and calculates the total and regional 
(R) average electrostatic entropy values θk(R) for each query protein. 
 
 
 
Figure 3. Web-user interface of LECTINPred online tool (http://bio-
aims.udc.es/LECTINPred.php). 
  
3.2.2. Mining PDB with LECTINPred (Example of use of Mode 1) 
Both the existence in PDB of +3000 proteins with unknown function and the interest on the discovery 
of new Ls (potential drug targets in parasite infections or cancer biomarkers) prompt us to carry out a 
data-mining search of new Ls candidates in PDB. For this study, we have implemented the key function 
PDB mining in the new server LECTINPred. By clicking this key the server performs automatic search of 
all PDB files with unknown function at a reference date. After that, LECTINPred extracts all Cα 
coordinates from these files and calculates the necessary πk(R) values for all these proteins. Last, the 
server uses these values as inputs of the best model found and predicts the S(Ls) values for all these 
proteins. The proteins with the highest scores may be selected as candidates for experimental assays in 
order to confirm the Ls function. Each time we use the PDB mining key, the server updates the prediction 
for all new PDB files present in the last version of the PDB synchronized with LECTINPred. We have 
predicted S(Ls) values for a total of 2693 proteins selected to have an unknown function (or only a 
hypothetical function predicted) and low sequence homology in current PDB release. Only 59 out of a 
total of 1368 proteins studied (released to PDB with unknown function) were predicted as possible Ls 
with S(Ls) >70 %, from those only 8 presented as S(Ls) >80 %. It means that LECTINPred has a low 
propensity to predict unknown proteins as Ls (only 0.58 % of the studied proteins have S(Ls) >80 %). In 
our opinion, this result is coherent with the relative low abundance of Ls in nature with respect to other 
functions. We depict the higher S(Ls) values found in the Supporting Information 2. These possible new 
Ls, if confirmed, may be useful as cancer biomarkers or in parasite vaccine design. 
3.2.3. LECTINPred Mode 2 
There are other potential uses of this server. How should one predict S(Ls) values for proteins with 
known sequence but unknown 3D structure and function that have not been released to PDB? Mode 2 is 
essentially the same as mode 1, but the server prompts the users to upload .ent and .pdb files with 3D 
structures of proteins generated by using LOMETS web server55 developed by Prof. Zhang et al. at 
Michigan University. Figure 3 depicts the user interface for LECTINPred mode 2 (bottom of the web 
page). LOMETS is a local threading meta-server, for quick and automated predictions of protein tertiary 
structures and spatial constraints. The LOMETS server is freely available to the academic community at 
http://zhang.bioinformatics.ku.edu/LOMETS. The mode 2 can also upload pdb files of protein 3D 
structural models generated with other structure prediction web servers like PHYRE256 
(http://www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?id=index). After generating PDB files with LOMETS, 
we can upload them to LECTINPred. This is the same strategy used to develop the mode 2 of the web 
server MIND-BEST, in order to predict drug-target interactions between drugs and proteins with 
unknown 3D structure.57 Anyhow, we have to be aware that using this input mode 2 we can predict S(Ls) 
values using 3D structural models generated only by modeling. Consequently, predictions derived with 
input mode 2 have to be used with more caution than predictions obtained with input mode 1. 
4. Conclusions 
The discovery of new Ls is a goal of great importance and several authors have presented interesting 
results. The present work has demonstrated that there is a strong linear relationship between 3D 
electrostatic field entropies calculated with the MARCH-INSIDE approach and the propensity of proteins 
to act as Ls. Consequently, using these parameters we can seek a linear QSAR useful to predict Ls. In 
addition, as user-friendly and publicly accessible web-servers represent the future direction of developing 
practically more useful predictors,58 we have introduced the web-server LECTINPred at http://bio-
aims.udc.es/LECTINPred.php. The online implementation of this model in the web server LECTINPred 
allows public researchers around the world to predict online new Ls at no cost. LECTINPred may be used 
to mine the PDB. We have demonstrated the PDB mining option performing a predictive study of +1000 
proteins with unknown function looking for new Ls. The user can also predict Ls scores for new protein 
sequences if uploads to LECTINPred the 3D models of proteins with unknown structure generated with 
well-known servers as in the case of LOMETS. The new Ls are expected to be of relevance as cancer 
biomarkers or useful in parasite vaccine design. 
  
Acknowledgements 
This work was financially supported by the Research Projects AGL2010-22290-C03-01 and 
AGL2011-30563-C03-01 from the Ministry of Science and Innovation, Spain. Munteanu CR thanks the 
Isidro Parga Pondal Research Program funded by Xunta de Galicia and the European Social Funds (ESF) 
for partial financial support. 
References 
1. L. M. van den Berg, S. I. Gringhuis, T. B. Geijtenbeek, Ann. N. Y. Acad. Sci. 2012, 1253, 149–158. 
2. J. J. Garcia-Vallejo, Y. van Kooyk, Immunol. Rev. 2009, 230, 22–37. 
3. T. B. Geijtenbeek, S. I. Gringhuis, Nat. Rev. Immunol. 2009, 9, 465–479. 
4. A. Osanya, E. H. Song, K. Metz, R. M. Shimak, P. M. Boggiatto, E. Huffman, C. Johnson, J. M. Hostetter, N. L. 
Pohl, C. A. Petersen, in Am. J. Pathol., Vol. 179, American Society for Investigative Pathology, Elsevier, New 
York, 2011, pp. 1329–1337. 
5. A. R. Young, G. J. Barcham, H. E. McWilliam, D. M. Piedrafita, E. N. Meeusen, in Vet. Immunol. Immunopathol., 
Elsevier, Amsterdam, 2012, pp. 362–367. 
6. H. C. McAllister, A. J. Nisbet, P. J. Skuce, D. P. Knox, in J. Helminthol., 2011, pp. 1–7. 
7. W. K. Ip, K. Takahashi, R. A. Ezekowitz, L. M. Stuart, Immunol. Rev. 2009, 230, 9–21. 
8. a) J. G. Geng, M. Chen, K. C. Chou, Curr. Med. Chem. 2004, 11, 2153–2160; b) K. C. Chou, FEBS Lett. 1995, 
363, 123–126; c) K. C. Chou, J. Protein Chem. 1996, 15, 161–168; d) K. C. Chou, R. L. Heinrikson, J. Protein 
Chem. 1997, 16, 765–773. 
9. P. Garred, C. Honore, Y. J. Ma, L. Munthe-Fog, T. Hummelshoj, Mol. Immunol. 2009, 46, 2737–2744. 
10. H. Y. Lei, C. P. Chang, J. Biomed. Sci. 2009, 16, 10. 
11. I. Mladenovic, L. Hajdukovic, O. Genbacev, M. Cuperlovic, M. Movsesijan, Hum. Reprod. 1993, 8, 258–265. 
12. M. Vasil′chuk Iu, N. F. Pogorelaia, N. S. Tkachenko, Klin. Khir. 1992, 9–11. 
13. V. D. Winn, M. Gormley, A. C. Paquet, K. Kjaer-Sorensen, A. Kramer, K. K. Rumer, R. Haimov-Kochman, R. F. 
Yeh, M. T. Overgaard, A. Varki, C. Oxvig, S. J. Fisher, Endocrinology 2009, 150, 452–462. 
14. T. Kamoto, S. Satomura, T. Yoshiki, Y. Okada, F. Henmi, H. Nishiyama, T. Kobayashi, A. Terai, T. Habuchi, O. 
Ogawa, Jpn. J. Clin. Oncol. 2002, 32, 472–476. 
15. N. Kume, T. Kita, Curr. Opin. Lipidol. 2001, 12, 419–423. 
16. M. Noguchi, M. Thomas, H. Kitagawa, K. Kinoshita, N. Ohta, M. Nagamori, I. Miyazaki, Br. J. Cancer 1993, 67, 
1368–1371. 
17. R. Kumar, B. Panwar, J. S. Chauhan, G. P. Raghava, in BMC Res. Notes, Vol. 4, England, 2011, p. 237. 
18. a) J. Devillers, A. T. Balaban, Topological Indices and Related Descriptors in QSAR and QSPR, Gordon and 
Breach, The Netherlands, 1999; b) Q. S. Du, R. B. Huang, K. C. Chou, Curr. Protein Pept. Sci. 2008, 9, 248–260; 
c) Q. S. Du, R. B. Huang, Y. T. Wei, L. Q. Du, K. C. Chou, J. Comput. Chem. 2008, 29, 211–219; d) Q. S. Du, R. 
B. Huang, Y. T. Wei, Z. W. Pang, L. Q. Du, K. C. Chou, J. Comput. Chem. 2009, 30, 295–304; e) Q. Du, P. G. 
Mezey, K. C. Chou, J. Comput. Chem. 2005, 26, 461–470;  
18f. H. Wei, C. H. Wang, Q. S. Du, J. Meng, K. C. Chou, Med. Chem. 2009, 5, 305–317. 
19. S. Sirois, D. Giguere, R. Roy, Med. Chem. (Shariqah, United Arab Emirates) 2006, 2, 481–489. 
20. a) J. P. Zbilut, A. Giuliani, A. Colosimo, J. C. Mitchell, M. Colafranceschi, N. Marwan, C. L. Webber, Jr., V. N. 
Uversky, J. proteome Res. 2004, 3, 1243–1253; b) B. Shen, J. Bai, M. Vihinen, Prot. Eng. Des. Sel. 2008, 21, 37–
44. 
21. F. Torrens, G. Castellano, Curr. Proteomics 2009, 204–213. 
22. a) W. Chen, P. M. Feng, H. Lin, K. C. Chou, Nucleic Acids Res. 2013, 41, e68; b) W. Chen, H. Lin, P. M. Feng, 
C. Ding, Y. C. Zuo, K. C. Chou, PLoS ONE 2012, 7, e47843; c) K. C. Chou, Z. C. Wu, X. Xiao, Mol. BioSyst. 
2012, 8, 629–641; d) Y. Xu, J. Ding, L. Y. Wu, K. C. Chou, PLoS ONE 2013, 8, e55844; e) X. Xiao, P. Wang, 
W. Z. Lin, J. H. Jia, K. C. Chou, Anal. Biochem. 2013, 436, 168–177; f) K. C. Chou, Z. C. Wu, X. Xiao, PLoS 
ONE 2011, 6, e18258;  
23. L. Santana, E. Uriarte, H. González-Díaz, G. Zagotto, R. Soto-Otero, E. Mendez-Alvarez, J. Med. Chem. 2006, 
49, 1149–1156. 
24. H. González-Díaz, R. R. de Armas, R. Molina, Bioinformatics 2003, 19, 2079–2087. 
25. a) G. Aguero-Chapin, J. Varona-Santos, G. A. de la Riva, A. Antunes, T. Gonzalez-Villa, E. Uriarte, H. 
Gonzalez-Diaz, J. Proteome Res. 2009, 8, 2122–2128; b) R. Concu, M. A. Dea-Ayuela, L. G. Perez-Montoto, F. 
Bolas-Fernandez, F. J. Prado-Prado, G. Podda, E. Uriarte, F. M. Ubeira, H. Gonzalez-Diaz, J. Proteome Res. 
2009, 8, 4372–4382. 
26. H. González-Díaz, L. Saiz-Urra, R. Molina, L. Santana, E. Uriarte, J. Proteome Res. 2007, 6, 904–908. 
27. L. Santana, H. Gonzalez-Diaz, E. Quezada, E. Uriarte, M. Yanez, D. Vina, F. Orallo, J. Med. Chem. 2008, 51, 
6740–6751. 
28. D. Vina, E. Uriarte, F. Orallo, H. Gonzalez-Diaz, Mol. Pharm. 2009, 6, 825–835. 
29. H. Gonzalez-Diaz, F. Prado-Prado, F. M. Ubeira, Curr. Top. Med. Chem. 2008, 8, 1676–1690. 
30. H. González-Díaz, Y. González-Díaz, L. Santana, F. M. Ubeira, E. Uriarte, Proteomics 2008, 8, 750–778. 
31. a) H. González-Díaz, S. Vilar, L. Santana, E. Uriarte, Curr. Top. Med. Chem. 2007, 7, 1025–1039; b) R. Concu, 
M. A. Dea-Ayuela, L. G. Perez-Montoto, F. J. Prado-Prado, E. Uriarte, F. Bolas-Fernandez, G. Podda, A. Pazos, 
C. R. Munteanu, F. M. Ubeira, H. Gonzalez-Diaz, Biochim. Biophys. Acta 2009, 1794, 1784–1794; c). Vilar, H. 
Gonzalez-Diaz, L. Santana, E. Uriarte, J. Theor. Biol. 2009, 261, 449–458. 
32. C. R. Munteanu, J. M. Vazquez, J. Dorado, A. P. Sierra, A. Sanchez-Gonzalez, F. J. Prado-Prado, H. Gonzalez-
Diaz, J. Proteome Res. 2009, 8, 5219–5228. 
33. R. Concu, M. A. Dea-Ayuela, L. G. Perez-Montoto, F. J. Prado-Prado, E. Uriarte, F. Bolas-Fernandez, G. Podda, 
A. Pazos, C. R. Munteanu, F. M. Ubeira, H. Gonzalez-Diaz, Biochim. Biophys. Acta 2009, 1794, 1784–1794. 
34. R. Concu, M. A. Dea-Ayuela, L. G. Perez-Montoto, F. Bolas-Fernandez, F. J. Prado-Prado, G. Podda, E. Uriarte, 
F. M. Ubeira, H. Gonzalez-Diaz, J. Proteome Res. 2009, 8, 4372–4382. 
35. Y. Rodriguez-Soca, C. R. Munteanu, J. Dorado, A. Pazos, F. J. Prado-Prado, H. Gonzalez-Diaz, J. Proteome Res. 
2010, 9, 1182–1190. 
36. C. R. Munteanu, Y. Rodriguez-Soca, J. Dorado, J. Rabuñal, A. Pazos, H. González-Díaz, Polymer 2010, 51, 264–
273. 
37 a) H. González-Díaz, A. Pérez-Bello, E. Uriarte, Polymer 2005, 46, 6461–6473; b) H. González-Díaz, E. Uriarte, 
R. Ramos de Armas, Bioorg. Med. Chem. 2005, 13, 323–331. 
38. L. Saiz-Urra, H. González-Díaz, E. Uriarte, Bioorg. Med. Chem. 2005, 13, 3641–3647. 
39. R. Concu, G. Podda, E. Uriarte, H. Gonzalez-Diaz, J. Comput. Chem., J. Comput. Chem. 2009, 30, 1510–1520. 
40 a) H. Gonzalez-Diaz, L. Saiz-Urra, R. Molina, Y. Gonzalez-Diaz, A. Sanchez-Gonzalez, J. Comput. Chem. 2007, 
28, 1042–1048; b) H. Gonzalez-Diaz, R. Molina, E. Uriarte, FEBS Lett. 2005, 579, 4297–4301; c) R. Concu, G. 
Podda, E. Uriarte, H. Gonzalez-Diaz, J. Comput. Chem. 2009, 30, 1510–1520; d) H. González-Díaz, Y. Pérez-
Castillo, G. Podda, E. Uriarte, J. Comput. Chem. 2007, 28, 1990–1995. 
41. STATISTICA (data analysis software system), version 6.0, StatSoft.Inc., www.statsoft.com.Statsoft, Inc., 2002. 
42 a) A. Speck-Planche, M. T. Scotti, V. de Paulo-Emerenciano, Curr. Pharm. Des. 2010, 16, 2656–2665; b) A. 
Speck-Planche, M. N. D. S. Cordeiro, Current Bioinformatics 2011, 6, 81–93; c) A. Speck-Planche, M. T. Scotti, 
V. P. Emerenciano, A. García-López, E. Molina-Pérez, E. Uriarte, J. Comput. Chem. 2010, 31, 882–894; d) A. 
Speck-Planche, M. T. Scotti, A. García-López, V. P. Emerenciano, E. Molina-Pérez, E. Uriarte, Mol. Divers. 
2009, 13, 445–458; e) G. M. Casanola-Martin, M. T. Khan, Y. Marrero-Ponce, A. Ather, M. N. Sultankhodzhaev, 
F. Torrens, Bioorg. Med. Chem. Lett. 2006, 16, 324–330; f) G. M. Casanola-Martin, Y. Marrero-Ponce, M. T. 
Khan, A. Ather, K. M. Khan, F. Torrens, R. Rotondo, Eur. J. Med. Chem. 2007, 42, 1370–1381; g) G. M. 
Casanola-Martin, Y. Marrero-Ponce, M. T. Khan, A. Ather, S. Sultan, F. Torrens, R. Rotondo, Bioorg. Med. 
Chem. 2007, 15, 1483–1503; h) G. M. Casanola-Martin, Y. Marrero-Ponce, M. Tareq Hassan Khan, F. Torrens, 
F. Perez-Gimenez, A. Rescigno, J. Biomol. Screen. 2008, 13, 1014–1024. 
43 a) A. Speck-Planche, L. Guilarte-Montero, R. Yera-Bueno, J. A. Rojas-Vargas, A. Garcia-Lopez, E. Uriarte, E. 
Molina-Perez, Pest. Manag. Sci. 2011, 67, 438–445; b) A. Speck-Planche, V. V. Kleandrova, J. A. Rojas-Vargas, 
Mol. Divers. 2011, 15, 901–909; c) A. Speck-Planche, V. V. Kleandrova, F. Luan, M. N. Cordeiro, Bioorg. Med. 
Chem. 2011, 19, 6239–6244. 
44 a) Y. Marrero-Ponce, R. Medina-Marrero, A. E. Castro, R. Ramos de Armas, H. González-Díaz, V. Romero-
Zaldivar, F. Torrens, Molecules 2004, 9, 1124–1147; b). Ramos de Armas, H. Gonzalez Diaz, R. Molina, E. 
Uriarte, Proteins 2004, 56, 715–723; c) R. Ramos de Armas, H. González-Díaz, R. Molina, M. Perez Gonzalez, 
E. Uriarte, Bioorg. Med. Chem. 2004, 12, 4815–4822; d)R. Ramos de Armas, H. González-Díaz, R. Molina, E. 
Uriarte, Biopolymers 2005, 77, 247–256; e) A. Speck-Planche, M. T. Scotti, V. de Paulo-Emerenciano, Curr. 
Pharm. Des., 16, 2656–2665. 
45. K. C. Chou, C. T. Zhang, Crit. Rev. Biochem. Mol. Biol. 1995, 30, 275–349. 
46. K. C. Chou, J. Theor. Biol. 2011, 273, 236–247. 
47. lit a) M. Hayat, A. Khan, J. Theor. Biol. 2011, 271, 10–17; b)K. K. Kandaswamy, K. C. Chou, T. Martinetz, S. 
Moller, P. N. Suganthan, S. Sridharan, G. Pugalenthi, J. Theor. Biol. 2011, 270, 56–62; c) K. C. Chou, Proteins 
2001, 43, 246–255; d) P. Zakeri, B. Moshiri, M. Sadeghi, J. Theor. Biol. 2011, 269, 208–216; e) K. C. Chou, 
Bioinformatics 2005, 21, 10–19; f) H. Mohabatkar, Protein Pept. Lett. 2010, 17, 1207–1214; g) H. Mohabatkar, 
M. M. Beigi, K. Abdolahi, S. Mohsenzadeh, Med. Chem. 2013, 9, 133–137. 
48. V. A. Ivanisenko, S. S. Pintus, D. A. Grigorovich, N. A. Kolchanov, Nucleic Acids Res. 2005, 33, D183–187. 
49. P. D. Dobson, A. J. Doig, J. Mol. Biol. 2003, 330, 771–783. 
50 a) Z. C. Wu, X. Xiao, K. C. Chou, Mol. BioSyst. 2011, 7, 3287–3297; b) X. Xiao, Z. C. Wu, K. C. Chou, J. Theor. 
Biol. 2011, 284, 42–51; c) K. C. Chou, Z. C. Wu, X. Xiao, Mol. BioSyst. 2012, 8, 629–641; d) X. Xiao, Z. C. 
Wu, K. C. Chou, PLoS ONE 2011, 6(6), e20592. 
51 a) M. Perez Gonzalez, A. Morales Helguera, J. Comput. Aided Mol. Des. 2003, 17, 665–672; b) Y. Marrero-
Ponce, R. Medina-Marrero, F. Torrens, Y. Martinez, V. Romero-Zaldivar, E. A. Castro, Bioorg. Med. Chem. 
2005, 13, 2881–2899; c) Y. Marrero-Ponce, A. Montero-Torres, C. R. Zaldivar, M. I. Veitia, M. M. Perez, R. N. 
Sanchez, Bioorg. Med. Chem. 2005, 13, 1293–1304; d) H. González-Díaz, A. Sanchez-Gonzalez, Y. Gonzalez-
Diaz, J. Inorg. Biochem. 2006, 100, 1290–1297. 
52. H. Van Waterbeemd, in Method and Principles in Medicinal Chemistry, Vol. 2 (Eds: R. Manhnhold, P. 
Krogsgaard-Larsen, H. Timmerman, H. Van Waterbeemd), Wiley-VCH, New York, 1995, pp. 283–293. 
53 a) H. B. Shen, K. C. Chou, Anal. Biochem. 2008, 373, 386–388; b) H. B. Shen, K. C. Chou, Protein Eng. Des. Sel. 
2007, 20, 561–567; c) K. C. Chou, H. B. Shen, Biochem. Biophys. Res. Commun. 2007, 357, 633–640; d) K. C. 
Chou, H. B. Shen, Nat. Protoc. 2008, 3, 153–162. 
54 a) K. C. Chou, J. Proteome Res. 2005, 4, 1413–1418; b) K. C. Chou, D. W. Elrod, J. Proteome Res. 2002, 1, 429–
433; c) K. C. Chou, D. W. Elrod, J. Proteome Res. 2003, 2, 183–190; d) K. C. Chou, H. B. Shen, J. Proteome 
Res. 2006, 5, 1888–1897; e) K. C. Chou, H. B. Shen, J. Proteome Res. 2006, 5, 3420–3428. 
55. S. Wu, Y. Zhang, Nucleic Acids Res. 2007, 35, 3375–3382. 
56. L. A. Kelley, M. J. Sternberg, Nat. Protoc. 2009, 4, 363–371. 
57. H. Gonzalez-Diaz, F. Prado-Prado, X. Garcia-Mera, N. Alonso, P. Abeijon, O. Caamano, M. Yanez, C. R. 
Munteanu, A. Pazos, M. A. Dea-Ayuela, M. T. Gomez-Munoz, M. M. Garijo, J. Sansano, F. M. Ubeira, J. 
Proteome Res. 2011, 10, 1698–1718. 
58. K. C. Chou, H. B. Shen, Natural Science 2009, 2, 63–92. 
 
